Ezetimibe

Source: www.moreover.com --- 9 days ago
Extract not available. ...

Source: www.ncbi.nlm.nih.gov --- 37 days ago
Related Articles Analyses of Cancer Data from Three Ezetimibe Trials. N Engl J Med. 2008 Sep 2; Authors: Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R BACKGROUND: Five years of statin therapy lowers low-density lipoprotein (LDL) cholesterol substantially and, over a 5-year period, results in reductions in the incidence of cardiovascular events. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial (ClinicalTrials.gov number, NCT00092677) has raised the hypothesis that adding Ezetimibe to statin therapy for larger LDL cholesterol reductions might increase the incidence of cancer. METHODS: We compared the results of a hypothesis-generating analysis of the incidence of cancer in the SEAS trial of Ezetimibe plus simvastatin in 1873 patients (mean follow-up after Ezetimibe or matching placebo was begun, 4.1 years) with a hypothesis-testing analysis of cancer data from the two large ongoing trials of this regimen: the Study of Heart and Renal Protection (SHARP) (NCT00125593) with 9264 patients (mean follow-up, 2.7 years) and the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) (NCT00202878), currently with 11,353 patients (mean follow-up, 1.0 year). RESULTS: In the SEAS trial, assignment to Ezetimibe was associated with an increase in any new onset of cancer (101 patients in the active-treatment group vs. 65 in the control group) from several cancer sites. In SHARP and IMPROVE- ...

Source: www.ncbi.nlm.nih.gov --- 37 days ago
Related Articles Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med. 2008 Sep 2; Authors: Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjærpe T, Wachtell K, Willenheimer R, BACKGROUND: Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results. METHODS: We conducted a randomized, double-blind trial involving 1873 patients with mild-to-moderate, asymptomatic aortic stenosis. The patients received either 40 mg of simvastatin plus 10 mg of Ezetimibe or placebo daily. The primary outcome was a composite of major cardiovascular events, including death from cardiovascular causes, aortic-valve replacement, nonfatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary-artery bypass grafting, percutaneous coronary intervention, and nonhemorrhagic stroke. Secondary outcomes were events related to aortic-valve stenosis and ischemic cardiovascular events. RESULTS: During a median follow-up of 52.2 months, the primary outcome occurred in 333 patients (35.3%) in the simvastatin-Ezetimibe group and in 355 patients (38.2%) in the placebo group (hazard ratio in the simvastatin-Ezetimibe group, 0.96; 95% confidence interval [CI], 0.83 to 1.12; P=0.59). Aortic-valve replacement was performed in ...

Source: www.ncbi.nlm.nih.gov --- 37 days ago
Related Articles Ezetimibe and Cancer -- An Uncertain Association. N Engl J Med. 2008 Sep 2; Authors: Drazen JM, D'Agostino RB, Ware JH, Morrissey S, Curfman GD PMID: 18765434 [PubMed - as supplied by publisher] ...

Source: www.medicalnewstoday.com --- 39 days ago
The link between cholesterol-lowering drug Ezetimibe (marketed as Vytorin) and cancer is still not clear, wrote the editors of the leading medical journal New England Journal of Medicine (NEJM). More time is needed to assess the drug, they said, and in the meantime patients and doctors will have to live with the uncertainty. ...

Source: www.medpagetoday.com --- 40 days ago
MUNICH (MedPage Today) -- More than four years of intensive lipid-lowering therapy with Ezetimibe/simvastatin (Vytorin) did not slow the progress of aortic stenosis, researchers reported here. ...

Source: www.medpagetoday.com --- 38 days ago
SEATTLE (MedPage Today) -- Simvastatin/Ezetimibe (Vytorin) may increase the risk of cancer after all, concluded a leading American biostatistician who dismissed as prematurely reassuring an analysis by Richard Peto, Ph.D., F.R.S., that found the link with excess malignancy to be overblown. ...

Source: www.news-medical.net --- 40 days ago
The SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study has investigated the effects of intensive cholesterol lowering with the combination of simvastatin (40 mg daily) and Ezetimibe (10 mg daily) in patients with aortic stenosis. ...

Source: www.healthcarerepublic.com --- 39 days ago
GPs should continue to prescribe Ezetimibe despite research linking the drug to an increased risk of cancer. ...

Source: www.rxlist.com --- 35 days ago
Vytorin (Ezetimibe & Simvastatin) drug description - FDA approved labeling for prescription drugs and medications at RxList ...

Source: www.pharmacist.com --- 26 days ago
An analysis of three clinical trials concludes that there is no convincing evidence supporting a link between Vytorin and cancer risk; however, some clinicians continue to express concern about the safety of the drug. ...

Source: www.npci.org.uk --- 23 days ago
Rossebø AB, et al for the SEAS Investigators. Intensive lipid lowering with simvastatin and Ezetimibe in aortic stenosis. N Engl J Med 2008; 359 (early online publication, September 2nd 2008: 10.1056/NEJMoa0804602) Peto R, et al. Analyses of cancer data from three Ezetimibe trials. N Engl J Med 2008;359 (early online publication September 2nd 2008: 10/1056/NEJMsa0806603) This trial [...] ...

Source: scienceblogs.com --- 39 days ago
Cutting to chase for those of you who want a quick answer: we don't know, there aren't enough people to study yet. There are hints, though. Ezetimibe is commonly used in combination with a statin as Vytorin to reduce heart disease in patients. It doesn't work all that well. I should say, it decreases cholesterol fine but whether that leads to less overall heart disease isn't conclusive ( latest study released today says maybe a little). Of course that study found an increase in cancer in those taking the drug. However, another analysis released today found that cancer deaths were increased but cancer cases were decreased (both were on the verge of stastical significance). Based on that reverse finding alone, it seems that not much is happening here, or if there is, not much. Animal studies show nothing that would indicate a problem. This seems like a bit of ho hum but think about what this means for drug approval for a second. This drug was approved in 2002. It's 2008 and we don't really know if it decreases death an disease. This is the problem with approving on surrogate markers - that's where the FDA says "well, you don't know if it reduces heart disease but you know it decreases cholesterol and those are known to be related so good enough". Sadly, this is very common with many types of drugs. The problems with this approach are four-fold (at least): One, there may be a diluted association. For instance, if there is a certain amount ...

Source: www.cardiovascularpharm.com --- 29 days ago
Page: 145 DOI: 10.1097/FJC.0b013e31817ffe76 Authors: Olijhoek, Jobien K MD, PhD *; Hajer, Gideon R MD, PhD *; Graaf, Yolanda van der MD, PhD +; Dallinga-Thie, Geesje M PhD ++; Visseren, Frank L J MD, PhD * ...

Source: camdic.newsvine.com --- 38 days ago
Five years of statin therapy lowers low-density lipoprotein (LDL) cholesterol substantially and, over a 5-year period, results in reductions in the incidence of cardiovascular events. ...

Source: news.google.com --- 38 days ago
ChattahBox Drug Scare Shenanigans FOXNews - 2 hours ago By Steven Milloy Why is the editor of the New England Journal of Medicine encouraging a cancer scare over the cholesterol-lowering drug Vytorin? Peto Analysis Called Short on Proof of Simvastatin/Ezetimibe ... MedPage Today Top Statistician Says Vytorin Cancer Risk 'Not Ruled Out' Forbes Reuters  - U.S. News & World Report  - MedHeadlines  - eFluxMedia all 529 news articles ...

Source: news.google.com --- 39 days ago
Boston Globe Health Buzz: More Vytorin Studies and Other Health News U.S. News & World Report - 4 hours ago A three-study analysis, published yesterday in the New England Journal of Medicine, did not find compelling evidence linking the cholesterol-lowering drug Vytorin (Ezetimibe) to an increased risk of cancer. Vytorin Study's Ethical Morass Forbes Medical Journal Raises Concern About Vytorin Wall Street Journal New York Times  - Washington Post  - USA Today  - WebMD all 489 news articles ...

Source: www.moreover.com --- 28 days ago
Trials measuring major cardiovascular events as an endpoint are the best evidence to determine if an intervention such as Ezetimibe conveys benefit At an American College of Cardiology meeting in Chicago earlier this year, the long-awaited results of ...

Source: www.ncbi.nlm.nih.gov --- 3 hours ago
Related Articles SREBP-2 regulates gut peptide secretion through intestinal bitter taste receptor signaling in mice. J Clin Invest. 2008 Oct 9; Authors: Jeon TI, Zhu B, Larson JL, Osborne TF Bitter taste-sensing G protein-coupled receptors (type 2 taste receptors [T2Rs]) are expressed in taste receptor cells of the tongue, where they play an important role in limiting ingestion of bitter-tasting, potentially toxic compounds. T2Rs are also expressed in gut-derived enteroendocrine cells, where they have also been hypothesized to play a role in limiting toxin absorption. In this study, we have shown that T2R gene expression in both cultured mouse enteroendocrine cells and mouse intestine is regulated by the cholesterol-sensitive SREBP-2. In addition, T2R stimulation of cholecystokinin (CCK) secretion was enhanced directly by SREBP-2 in cultured cells and in mice fed chow supplemented with lovastatin and Ezetimibe (L/E) to decrease dietary sterol absorption and increase nuclear activity of SREBP-2. Low-cholesterol diets are naturally composed of high amounts of plant matter that is likely to contain dietary toxins, and CCK is known to improve dietary absorption of fats, slow gastric emptying, and decrease food intake. Thus, these studies suggest that SREBP-2 activation of bitter signaling receptors in the intestine may sensitize the gut to a low-fat diet and to potential accompanying food-borne toxins that make it past the initial aversi ...

Source: www.ncbi.nlm.nih.gov --- 34 days ago
Related Articles Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31 Authors: Tomillero A, Moral MA 11D10, 9vPnC-MnCc; Adalimumab, Adefovir dipivoxil, Alefacept, ALN-RSV01, AME-133, AMG-317, Aminolevulinic acid methyl ester, Amlodipine besylate/atorvastatin calcium, Anisodamine, Anti-IL-5 receptor antibody, Apremilast, Aripiprazole, Atacicept, Atazanavir sulfate, Atrasentan; Banoxantrone, Bevacizumab, BIBW-2992, Binodenoson, BMS-387032; cAC10, Caldaret hydrate, CD-NP, Ceftobiprole medocaril, Celivarone fumarate, Certolizumab pegol, Cholesteryl hydrophobized polysaccharide-Her2 protein complex, Choline fenofibrate, Cilengitide, Cinaciguat, Curcumin, Custirsen sodium, Cypher, CYT-6091; Dalcetrapib, Deforolimus, Desvenlafaxine succinate, DHA-paclitaxel, DP6-001; E-7010, E75, Ecogramostim, EGF-P64K, EnvPro, Enzastaurin hydrochloride, Escitalopram oxalate, Ezetimibe, Ezetimibe/simvastatin; Fenretinide; Gefitinib, Golimumab, Green tea catechins, GTI-2040, GW-406381; HPV16 E6 E7, HPV-16/18 AS04, HPV-6/11/16/18; ICC-1132, Immune globulin intravenous (human), Indacaterol, Intranasal insulin; Kahalalide F; Lactobacillus rhamnosus, Laromustine, Laropiprant, GTI-2040; MAb 3H1, Mepolizumab, Mifamurtide, Milataxel, MP4; Nebicapone, Nelarabine, Neuradiab; Oncolytic HSV; PCV7, PHX-1149, Pimecrolimus, Pralatrexate, Pramiconazole; Ranibizumab, Reolysin, Rilonacept, Rolofylline, Romidepsin; S-32865, Shigella dysenteriae 1 v ...